Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
national top stories
life sciences
boston blog main
boston top stories
clinical trials
san francisco blog main
san francisco top stories
texas blog main
texas top stories
austin
biotech
data
drugs
fda
funding
houston
innovation
investment
ipo
medical device
new york blog main
new york top stories
people
robotics/ai
san antonio
san francisco
software
startups
texas
venture capital
accelerated approval
acute hepatic porphyria
adha
agilecraft
alafair bioscienes
alnylam pharmaceuticals
alto
amgen
aminolevulinic acid
What
nasdaq
7
×
based
drug
latest
medicine
therapeutics
big
catch
innovation
ipo
let’s
million
new
news
public
tech
texas
tx
week
year
aces
acquired
agilecraft
agilecraft’s
alnylam
announced
apiece
atlassian
australia
benefit
biotechs
british
candidate
cannabis
ceo
cholesterol
cleared
closing
club
columbia
Language
unset
Current search:
nasdaq
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
AgileCraft’s Exit, $45M for Ojo Labs, Intel Grants & More TX Tech
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@techcrunch.com
5 years ago
Public shareholders got high today on Tilray, the first marijuana company to IPO on Nasdaq
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M